Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint‐inhibitor pneumonitis: A case report and literature review
Abstract Background For programmed death‐ligand‐1 (PD‐L1) positive recurrent and metastatic head and neck squamous cell carcinoma (R/M‐HNSCC), KEYNOTE‐048 and KEYNOTE‐040 clinical trials recently approved pembrolizumab monotherapy as first‐line treatment. However, recurrent and metastatic sinonasal...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-07-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1778 |